{"postID":136121264,"cachedAt":715124223.68664098,"updatedAt":715124223.68662906,"content":{"type":"doc","content":[{"type":"captionedImage","content":[{"type":"image2","attrs":{"topImage":false,"srcNoWatermark":null,"bytes":674281,"href":null,"width":1456,"fullscreen":null,"belowTheFold":false,"type":"image\/png","title":null,"internalRedirect":null,"src":"https:\/\/substack-post-media.s3.amazonaws.com\/public\/images\/b7e49501-662e-44ea-b4fa-c3ceb4578f86_2048x2048.png","height":1456,"imageSize":null,"resizeWidth":null,"alt":null}}]},{"type":"paragraph","content":[{"type":"text","text":"Results:"}]},{"type":"paragraph","content":[{"type":"text","text":"“Reductions in excess deaths over a period of 30 days after peak deaths averaged 74% in the 10 states with the most intensive IVM use. As determined across all 25 states, these reductions in excess deaths correlated closely with the extent of IVM use (p<0.002). During four months of IVM use in 2020, before a new president of Peru restricted its use, there was a 14-fold reduction in nationwide excess deaths and then a 13-fold increase in the two months following the restriction of IVM use. Notably, these trends in nationwide excess deaths align with WHO summary data for the same period in Peru.”"}]},{"type":"paragraph","content":[{"type":"text","text":"Study: "},{"type":"text","text":"https:\/\/assets.cureus.com\/uploads\/original_article\/pdf\/172991\/20230808-24035-iz4bd8.pdf","marks":[{"type":"link","attrs":{"target":"_blank","href":"https:\/\/assets.cureus.com\/uploads\/original_article\/pdf\/172991\/20230808-24035-iz4bd8.pdf","class":null}}]}]}]}}